Katie E Lichter, Alyssa Asaro, Muhammad Mustafa Qureshi, Minh Tam Truong, Akash Parekh, Alon Witztum, Chirjiv Anand, Genevieve S Silva, Trevor Royce, Nicholas G Zaorsky, Surbhi Grover, May Abdel-Wahab, Cassandra Thiel, Matthew J Eckelman, Nicolas Prionas, Sue S Yom, Osama Mohamad
{"title":"美国放射治疗对气候和健康的影响:估计温室气体排放、DALYs和低分割的潜力。","authors":"Katie E Lichter, Alyssa Asaro, Muhammad Mustafa Qureshi, Minh Tam Truong, Akash Parekh, Alon Witztum, Chirjiv Anand, Genevieve S Silva, Trevor Royce, Nicholas G Zaorsky, Surbhi Grover, May Abdel-Wahab, Cassandra Thiel, Matthew J Eckelman, Nicolas Prionas, Sue S Yom, Osama Mohamad","doi":"10.1016/j.radonc.2025.111161","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/purpose: </strong>Climate change is a global crisis, with the healthcare sector contributing 8.5-10% of greenhouse gas (GHG) emissions in the United States (U.S.). Radiation oncology, particularly through patient transportation for external beam radiation therapy (EBRT), is known to contribute to these emissions. In this study, we aim to quantify the annual GHG emissions in carbon dioxide equivalents (CO<sub>2</sub>e) from EBRT in the U.S., estimate their down-stream impact on human health in terms of disability-adjusted life-years (DALYs) lost, and evaluate the potential reduction in emissions through increased adoption of hypofractionation, using early-stage breast cancer as a model.</p><p><strong>Materials/methods: </strong>This is a retrospective analysis using life cycle assessment (LCA) methodologies, integrating real-world data on patient transportation and energy use, and simulations of alternative fractionation schedules following previously established breast treatment guidelines. The study included 556,426 patients who received EBRT for nine cancer types (breast, central nervous system, gastrointestinal, genitourinary, gynecological, head and neck, musculoskeletal, skin, and thoracic), as recorded in the National Cancer Database (NCDB) in 2019 and 2020. Of these, 49,909 patients with early-stage breast cancer (stages I-II, node-negative) were modeled for hypofractionation scenarios.</p><p><strong>Results: </strong>In 2019 and 2020, EBRT treatments in the U.S. resulted in 3.3 and 2.7 million metric tonnes of CO<sub>2</sub>e, respectively. Corresponding DALYs lost were 1,040 in 2019 and 863 in 2020. Simulations showed that increasing use of hypofractionation for eligible breast cancer treatments could reduce GHG emissions by up to 64%.</p><p><strong>Conclusions: </strong>Establishing baseline U.S. GHG emissions from EBRT offers a foundation for identifying opportunities to mitigate emissions. Investigating clinical practices from an environmental perspective can yield dual benefits: improved quality of care and significant emissions reductions.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111161"},"PeriodicalIF":5.3000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The climate and health impact of U.S. radiation therapy: estimating greenhouse gas emissions, DALYs, and potential of hypofractionation.\",\"authors\":\"Katie E Lichter, Alyssa Asaro, Muhammad Mustafa Qureshi, Minh Tam Truong, Akash Parekh, Alon Witztum, Chirjiv Anand, Genevieve S Silva, Trevor Royce, Nicholas G Zaorsky, Surbhi Grover, May Abdel-Wahab, Cassandra Thiel, Matthew J Eckelman, Nicolas Prionas, Sue S Yom, Osama Mohamad\",\"doi\":\"10.1016/j.radonc.2025.111161\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/purpose: </strong>Climate change is a global crisis, with the healthcare sector contributing 8.5-10% of greenhouse gas (GHG) emissions in the United States (U.S.). Radiation oncology, particularly through patient transportation for external beam radiation therapy (EBRT), is known to contribute to these emissions. In this study, we aim to quantify the annual GHG emissions in carbon dioxide equivalents (CO<sub>2</sub>e) from EBRT in the U.S., estimate their down-stream impact on human health in terms of disability-adjusted life-years (DALYs) lost, and evaluate the potential reduction in emissions through increased adoption of hypofractionation, using early-stage breast cancer as a model.</p><p><strong>Materials/methods: </strong>This is a retrospective analysis using life cycle assessment (LCA) methodologies, integrating real-world data on patient transportation and energy use, and simulations of alternative fractionation schedules following previously established breast treatment guidelines. The study included 556,426 patients who received EBRT for nine cancer types (breast, central nervous system, gastrointestinal, genitourinary, gynecological, head and neck, musculoskeletal, skin, and thoracic), as recorded in the National Cancer Database (NCDB) in 2019 and 2020. Of these, 49,909 patients with early-stage breast cancer (stages I-II, node-negative) were modeled for hypofractionation scenarios.</p><p><strong>Results: </strong>In 2019 and 2020, EBRT treatments in the U.S. resulted in 3.3 and 2.7 million metric tonnes of CO<sub>2</sub>e, respectively. Corresponding DALYs lost were 1,040 in 2019 and 863 in 2020. Simulations showed that increasing use of hypofractionation for eligible breast cancer treatments could reduce GHG emissions by up to 64%.</p><p><strong>Conclusions: </strong>Establishing baseline U.S. GHG emissions from EBRT offers a foundation for identifying opportunities to mitigate emissions. Investigating clinical practices from an environmental perspective can yield dual benefits: improved quality of care and significant emissions reductions.</p>\",\"PeriodicalId\":21041,\"journal\":{\"name\":\"Radiotherapy and Oncology\",\"volume\":\" \",\"pages\":\"111161\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiotherapy and Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.radonc.2025.111161\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiotherapy and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.radonc.2025.111161","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
The climate and health impact of U.S. radiation therapy: estimating greenhouse gas emissions, DALYs, and potential of hypofractionation.
Background/purpose: Climate change is a global crisis, with the healthcare sector contributing 8.5-10% of greenhouse gas (GHG) emissions in the United States (U.S.). Radiation oncology, particularly through patient transportation for external beam radiation therapy (EBRT), is known to contribute to these emissions. In this study, we aim to quantify the annual GHG emissions in carbon dioxide equivalents (CO2e) from EBRT in the U.S., estimate their down-stream impact on human health in terms of disability-adjusted life-years (DALYs) lost, and evaluate the potential reduction in emissions through increased adoption of hypofractionation, using early-stage breast cancer as a model.
Materials/methods: This is a retrospective analysis using life cycle assessment (LCA) methodologies, integrating real-world data on patient transportation and energy use, and simulations of alternative fractionation schedules following previously established breast treatment guidelines. The study included 556,426 patients who received EBRT for nine cancer types (breast, central nervous system, gastrointestinal, genitourinary, gynecological, head and neck, musculoskeletal, skin, and thoracic), as recorded in the National Cancer Database (NCDB) in 2019 and 2020. Of these, 49,909 patients with early-stage breast cancer (stages I-II, node-negative) were modeled for hypofractionation scenarios.
Results: In 2019 and 2020, EBRT treatments in the U.S. resulted in 3.3 and 2.7 million metric tonnes of CO2e, respectively. Corresponding DALYs lost were 1,040 in 2019 and 863 in 2020. Simulations showed that increasing use of hypofractionation for eligible breast cancer treatments could reduce GHG emissions by up to 64%.
Conclusions: Establishing baseline U.S. GHG emissions from EBRT offers a foundation for identifying opportunities to mitigate emissions. Investigating clinical practices from an environmental perspective can yield dual benefits: improved quality of care and significant emissions reductions.
期刊介绍:
Radiotherapy and Oncology publishes papers describing original research as well as review articles. It covers areas of interest relating to radiation oncology. This includes: clinical radiotherapy, combined modality treatment, translational studies, epidemiological outcomes, imaging, dosimetry, and radiation therapy planning, experimental work in radiobiology, chemobiology, hyperthermia and tumour biology, as well as data science in radiation oncology and physics aspects relevant to oncology.Papers on more general aspects of interest to the radiation oncologist including chemotherapy, surgery and immunology are also published.